Drugs

Toxin Alert Notice of Default Update

Tue, 23 Dec 2008 10:50:00 EST

TORONTO, ONTARIO--(eMediaWorld - Dec. 23, 2008) - Toxin Alert Inc. (TSX VENTURE:TOX) (the "Company") was unable to file its audited financial statements and other material for the fiscal year ended June 30, 2008 by the statutory deadline of October 29, 2008 and a Management Cease Trade Order was issued by the relevant securities authorities on October 29, 2008. This Default Status Report is issued pursuant to National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

TOPIGEN Pharmaceutiques initie le développement clinique de TPI 1100, un nouvel inhibiteur de PDE administré par inhalation, pour le traitement de la MPOC

Tue, 23 Dec 2008 10:39:00 EST

La société revoit ses priorités dans le développement de traitements de la MPOC

Metabolife, Nation's Most Respected Diet Company, Reveals Breakthrough Help on Yo-Yo Dieting

Mon, 22 Dec 2008 05:00:00 EST

NEW YORK, NY--(eMediaWorld - December 22, 2008) - Holding on to unhealthy fat after an initial weight loss happens to everyone. Even top celebrities' recurring battle with weight has been well documented in the press. This yo-yo tendency makes the self promise to lose weight one of the top New Year's pledges and keeps gyms in business when resoluteness for dieters annually fades by March. After successful dieting, the body can actually work against itself, slowing metabolism and making it harder to keep weight off. A patent pending combination of four common ingredients has been shown to help break through the body's natural tendency to hold on to unhealthy fat and slow its metabolism after initial weight loss. This year, dieters get help to keep their New Year's Resolution with the clinically tested and groundbreaking formula of cayenne, green tea, caffeine and the amino acid, L-Tyrosine that is found in Metabolife's "Break Through." Break Through is the first product of its kind

Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge From Board of Directors and Appointment of William Rueckert as Chairman of Audit Committee

Fri, 19 Dec 2008 08:15:00 EST

NEW CANAAN, CT--(eMediaWorld - December 19, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Stephen Breckenridge resigned as a member of the Board of Directors effective December 15, 2008 for personal reasons. Mr. Breckenridge was the Chairman of the Audit Committee and served as the audit committee financial expert. He also served as a member of the Compensation Committee. On December 18, 2008, the Board of Directors appointed William Rueckert, an existing member of the Board, as Chairman of the Audit Committee. The Board of Directors has determined that Mr. Rueckert qualifies as an audit committee financial expert. As a result of Mr. Breckenridge's resignation, the size of the Board of Directors has decreased from six to five members.

Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients

Fri, 19 Dec 2008 02:01:00 EST

LONDON and CAMBRIDGE, MA--(eMediaWorld - December 19, 2008) - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that the United States Food and Drug Administration (FDA) has approved its tablet formulation of fludarabine phosphate ('oral fludarabine') as a second-line treatment for chronic lymphocytic leukaemia (CLL). Oral fludarabine provides an alternative means to administer fludarabine that avoids the need for patients to have an intravenous infusion. Antisoma plans to make the drug available to US patients through a commercialisation deal. Talks are ongoing with a number of companies that have established oncology marketing operations in the US. Antisoma expects to conclude a deal early in 2009.

Critical Outcome Technologies Inc. Reports Second Quarter 2009 Financial Results

Thu, 18 Dec 2008 17:02:00 EST

LONDON, ONTARIO--(eMediaWorld - Dec. 18, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT) today announced financial results for its second quarter and the six months ended October 31, 2008. Selected Highlights The Company is pleased to report positive results on its research and development programs and organizational developments. Selected operating highlights during the quarter include: - The appointment of Mr. Michael Cloutier as Chief Executive Officer in October. Mr. Cloutier is a seasoned, senior executive with major pharmaceutical company background, experience and contacts, with his most recent role having been as a VP in Global Marketing at AstraZeneca.

Toxin Alert Inc. Closes First Tranche of Private Placement

Thu, 18 Dec 2008 14:18:00 EST

TORONTO, ONTARIO--(eMediaWorld - Dec. 18, 2008) - Toxin Alert Inc. (TSX VENTURE:TOX) announced that it closed the first tranche of its current private placement offering on December 17, 2008. The offering remains open until a final closing on or before December 31, 2008. The private placement was for the purpose of obtaining funds to complete the company's 2008 audit. The first tranche closing consisted of 650,000 units of one share and one-half warrant priced at $0.10 a unit. The warrants are for a term of two years and are exercisable at $0.15. The entire offering consists of 1,500,000 similar units. The funds in the first tranche are sufficient to deliver the audit for 2008, and work on the audit has commenced.

DSM and Crucell Announce PER.C6(R) License Agreement with CSL Ltd.

Thu, 18 Dec 2008 08:12:00 EST

LEIDEN, NETHERLANDS--(eMediaWorld - December 18, 2008) - Leiden, The Netherlands/Parsippany, USA, 18 December 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that CSL Limited, a global biopharmaceutical company headquartered in Melbourne, Australia, signed a license agreement allowing CSL to develop protein therapeutics for multiple undisclosed disease targets on the PER.C6® platform. Under the terms of the agreement, CSL is responsible for the development of protein and antibody products resulting from this alliance. Financial terms of the agreement were not disclosed.

GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM(R) Project

Tue, 16 Dec 2008 05:00:00 EST

REGENSBURG, GERMANY--(eMediaWorld - December 16, 2008) - - New HuCAL PLATINUM® antibody library is based on DNA components synthesized by GENEART - High quality of DNA components produced improves diversity and affinity of antibodies in new HuCAL PLATINUM® - Rational gene sequence design by GENEART's proprietary software GeneOptimizer® leads to significantly higher production rates in tested antibodies - Improved antibody library HuCAL PLATINUM® enables shortening of development timelines, i.e. for the development of promising drug candidates

Diazyme Introduces Liquid Stable Enzymatic Lithium Test

Mon, 15 Dec 2008 20:56:00 EST

SAN DIEGO, CA--(eMediaWorld - December 15, 2008) - Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its liquid stable enzymatic lithium test kit for the quantitative determination of lithium levels in blood samples. Compared to existing methods, the new Diazyme lithium assay provides improved reagent stability and a reduced cost per test. The assay features excellent accuracy and precision and offers an extended reportable range of 0.1-3.0 mmole/L lithium which will reduce the need for re-testing elevated patient samples. The method also demonstrates no significant interference from indigenous ions and other interfering substances including hemoglobin, bilirubin, triglycerides and ascorbic acid. The assay can be applied to most common clinical chemistry analyzers, and application parameters are available from Diazyme.

Proteonomix, Inc. Announces That Its Subsidiary, Proteoderm, Inc., Has Entered Into a Letter of Intent With Sinoquest Investment Limited for the Licensing, Purchase and Distribution of Proteoderm's Cosmoceutical Containing Its Patent-Pending Bioactive Protein Matrix

Mon, 15 Dec 2008 12:59:00 EST

MOUNTAINSIDE, NJ--(eMediaWorld - December 15, 2008) - Proteonomix, Inc. (PINKSHEETS: PROT) announces that its wholly-owned subsidiary, Proteoderm, Inc., and Sinoquest Investment Limited have signed a letter of intent (LOI), whereby, under a definitive agreement to be consummated, Sinoquest will gain exclusive rights in China, Taiwan, and Hong Kong to purchase for distribution of Proteoderm's revolutionary new stem cell-derived skin care products containing the bioactive protein matrix NC-138T. The products include Proteoderm's special high end formulation and an over-the-counter formulation, currently under development. Proteoderm intends to sell to Sinoquest the pre-mixed material in bulk and a license of its name and the right to use the material in Sinoquest's own containers. Both companies expect to begin distribution in the first quarter of 2009.

Peter and Valerie Kompaniez Honored With American Diabetes Association's Distinguished Service Achievement Award

Fri, 12 Dec 2008 14:58:00 EST

Peter & Valerie Kompaniez Receive Ross Hickey Award for Outstanding Service in Diabetes Research Funding

BridgeGate International and Healthation, Inc. Entered Into an Original Equipment Manufacturer Agreement

Fri, 12 Dec 2008 10:28:00 EST

DARIEN, IL--(eMediaWorld - December 12, 2008) - BridgeGate International www.bridgegateintl.com and Healthation, Inc. www.healthation.com have entered into an Original Equipment Manufacturer Agreement that enables Healthation to incorporate and market the BridgeGate® version 4.0 integration platform to Healthation customers as part of a combined system or suite of proprietary products. BridgeGate granted Healthation a non-exclusive license to incorporate the BridgeGate® integration platform within Healthation's AcceleHealth® Real-Time Benefit Management System and AboveHealth® EHealth Suite.

SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness

Thu, 11 Dec 2008 09:00:00 EST

RESEARCH TRIANGLE PARK, NC and GENEVA--(eMediaWorld - December 11, 2008) - SCYNEXIS, Inc. and Drugs for Neglected Diseases initiative (DNDi) announced today that they have extended their collaboration on vital drug discovery research and development of affordable and effective therapies for human African trypanosomiasis (also known as sleeping sickness) for an additional three years. Sleeping sickness is one of the most devastating diseases in sub-Saharan Africa. "SCYNEXIS believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases," said SCYNEXIS President & CEO Yves Ribeill. "We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness."

SCYNEXIS und DNDi setzen Kooperation zur Identifizierung von Wirkstoffkandidaten zur Behandlung der Schlafkrankheit fort

Thu, 11 Dec 2008 09:00:00 EST

RESEARCH TRIANGLE PARK, North Carolina, und GENF--(eMediaWorld - December 11, 2008) - SCYNEXIS, Inc. und DNDi (Drugs for Neglected Diseases initiative) gaben heute bekannt, dass die beiden Organisationen ihre Kooperation zur Erforschung und Entwicklung lebenswichtiger, erschwinglicher und wirksamer Behandlungsmöglichkeiten der afrikanischen Trypanosomiasis (auch als Schlafkrankheit bekannt) für weitere drei Jahre fortsetzen werden. Die Schlafkrankheit ist eine der verheerendsten Krankheiten in Subsahara-Afrika.

SCYNEXIS und DNDi setzen Kooperation zur Identifizierung von Wirkstoffkandidaten zur Behandlung der Schlafkrankheit fort

Thu, 11 Dec 2008 09:00:00 EST

RESEARCH TRIANGLE PARK, North Carolina, und GENF--(eMediaWorld - December 11, 2008) - SCYNEXIS, Inc. und DNDi (Drugs for Neglected Diseases initiative) gaben heute bekannt, dass die beiden Organisationen ihre Kooperation für die Erforschung und Entwicklung vitaler, erschwinglicher und wirksamer Behandlungsmethoden der afrikanischen Trypanosomiasis (auch als Schlafkrankheit bekannt) für weitere drei Jahre fortsetzen werden. Die Schlafkrankheit ist eine der verheerendsten Krankheiten in Subsahara-Afrika.

SCYNEXIS et DNDi étendent leur collaboration afin d'identifier des médicaments pour le traitement de la maladie du sommeil

Thu, 11 Dec 2008 09:00:00 EST

RESEARCH TRIANGLE PARK, NC and GENEVE, SUISSE--(eMediaWorld - December 11, 2008) - SCYNEXIS, Inc. et Drugs for Neglected Diseases initiative (DNDi) ont annoncé aujourd'hui l'extension de leur collaboration sur trois années supplémentaires en matière de recherche et développement de médicaments essentiels pour la mise à disposition de thérapies efficaces et abordables économiquement destinées à traiter la trypanosomiase africaine (connue aussi sous le nom de maladie du sommeil). La maladie du sommeil est l'une des maladies les plus dévastatrices d'Afrique sub-saharienne.

Edwards Lifesciences Projects 2009 EPS Growth of 15 to 19 Percent

Thu, 11 Dec 2008 08:30:00 EST

-- European Clinical Study of Edwards SAPIEN XT Commences -- Company Receives $23 Million LifeStent Milestone Payment

Pharmaceutical Companies Cut More Than 6,000 Sales Jobs: Cutting Edge Information Report Analyzes Sales Force Restructuring and Outlines Path Going Forward

Thu, 11 Dec 2008 08:18:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - December 11, 2008) - Pharmaceutical companies have slashed more than 6,000 U.S. sales reps from their ranks in 2008, and additional field sales force cutbacks are expected in early 2009 as companies continue to implement cost-cutting measures. These cutbacks come on the heels of several studies showing that oversized field sales forces have saturated the market and that physicians are increasingly reluctant to see reps in their offices. "Pharmaceutical Sales Management 2008," a report from biopharmaceutical business intelligence leader Cutting Edge Information (www.PharmaSalesManagement.com), analyzes the trends in pharmaceutical industry sales force restructuring. Drug companies' sales management teams can apply the report's data on sales force structures, investment, training, and in-field tactics to refocus their organizations to achieve maximum impact in the new marketplace.

Parkinson's Disease Can Affect More Than Just the Body: Online Survey Finds Many Patients and Caregivers Unprepared for the Mental and Behavioral Changes Associated With the Disease

Wed, 10 Dec 2008 13:36:00 EST

Phase III Clinical Research Study Recruiting People With Parkinson's Disease Experiencing Mental and Behavioral Changes

HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug

Tue, 09 Dec 2008 12:01:00 EST

HemaQuest Presents Results at American Society of Hematology Annual Meeting

bioRASI to Present at the 60th Indian Pharmaceutical Congress in New Delhi, India

Tue, 09 Dec 2008 11:36:00 EST

U.S.-Based, Global CRO to Present Its Approach to Optimizing ANDA and 505(b)(2) Programs

CEO of International Drug and Explosive Detection Firm - IDenta Corp. Decries Irresponsibility of Manufacturers Continuing to Sell Dangerous Heroin Drug Detectors

Tue, 09 Dec 2008 10:43:00 EST

JERUSALEM, ISRAEL--(eMediaWorld - December 9, 2008) - Identa Corp is releasing the press release as a response to the following letter issued by the director of one of the main competitor companies: http://www.drugsdetector.com/attachments/letter.pdf The CEO of International Drug & Explosives Firm IDenta Corp. (PINKSHEETS: IDTA) issued a policy statement today concerning the effectiveness claims and user safety of all IDenta products. The statement follows recent news that three other heroin drug detection products being sold in the U.S. and in international marketplaces may result not only in false positives, but also can convert some chemical compounds into dangerous and explosive sulfuric acid. Serious injuries to law enforcement officers have already been reported.

CLSI Releases Guidelines for Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory

Mon, 08 Dec 2008 10:16:00 EST

WAYNE, PA--(eMediaWorld - December 8, 2008) - A measured or observed laboratory test result from a person (usually a patient) is compared with a reference interval for the purpose of making a medical diagnosis, therapeutic management decision, or other physiological assessment. It is important to develop reference intervals using a systematic process that takes into account the various influences on the measured laboratory test results. Clinical and Laboratory Standards Institute (CLSI) recently published a document, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline -- Third Edition" (C28-A3), which offers a protocol for determining reference intervals that meet the minimum requirements for reliability and usefulness.

FDA Approves GlaxoSmithKline Tetanus, Diphtheria, Whooping Cough Vaccine, BOOSTRIX(R), for Adults

Mon, 08 Dec 2008 09:05:00 EST

New Indication for Booster Vaccine Expands Disease Protection to Individuals Aged 10-64 Years

Antisoma announces positive interim data from AS1411 phase II trial in acute myeloid leukaemia

Mon, 08 Dec 2008 02:06:00 EST

LONDON and CAMBRIDGE, MA and SAN FRANCISCO, CA--(eMediaWorld - December 8, 2008) - Study reported at ASH is first randomised trial of an aptamer in cancer A webcast and conference call about the ASH presentations on AS1411 and AS1413 will be held today at 9am GMT. The webcast can be accessed via Antisoma's website at www.antisoma.com and the calls by dialling +44 (0)20 8609 1435 (UK toll-free 0808 109 1498; US toll-free 1866 793 4279) and using the participant PIN code 965983#. A recording of the webcast will also be available afterwards on the Antisoma website. A separate press release will be made tomorrow regarding data on AS1413.

MattsonJack Releases Oncology Market Access Europe, Third Edition: Multi-Country Tool for Optimal Positioning, Pricing, and Coverage

Thu, 04 Dec 2008 10:05:00 EST

ST. LOUIS, MO--(eMediaWorld - December 4, 2008) - The Mattson Jack Group, Inc. (MattsonJack), a recognized leader in business analytics for the pharmaceutical and health care industries, announces the release of Oncology Market Access Europe, Third Edition, formerly Oncology Marketing Strategies Western Europe, the key resource for successful cancer drug positioning in the diverse and rapidly evolving European health care market. Oncology Market Access Europe is based on primary qualitative and quantitative research as well as comprehensive secondary analyses to provide the most current distillation of the market access situation by country and across the European Union (EU) Big 5 -- France, Germany, Italy, Spain, and the United Kingdom. The content helps subscribers position drugs for optimal pricing and coverage as well as create timely and country-specific strategies that best fit the ever-changing market access landscape. Research fo

Alzheimer's Drug Discovery Foundation Funds P2D to Develop Anti-Alzheimer's Disease Drug

Tue, 02 Dec 2008 16:26:00 EST

NEW YORK, NY--(eMediaWorld - December 2, 2008) - The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a biotechnology founder's grant of $300,000 to P2D Biosciences (P2D), a start-up biotechnology company dedicated to developing drugs that prevent Alzheimer's disease (AD). The grant will assist P2D develop novel compounds based on the drug thalidomide (Thalomid®, Celgene), which aims to prevent or slow neuronal cell death in AD. Thalidomide is currently approved for treating multiple myeloma and has been demonstrated to block the tumor necrosis factor-alpha (TNF-alpha) protein. Tumor necrosis factor is a mediator of neuronal cell death in response to inflammation and injury in the nervous system. Multiple lines of evidence suggest that TNF-alpha plays a role in AD.

Ahura Scientific Wins Second Cygnus Innovation Award

Tue, 02 Dec 2008 10:38:00 EST

Company Honored in HazMAT/WMD Category for TruDefender FT, Its Newest Handheld Chemical Identification Product

China Yongxin Pharmaceuticals, Inc. Establishes Retailing Chain Management Head Office to Uniformly Manage Its Growing Base of Chain Drugstores

Tue, 02 Dec 2008 09:00:00 EST

CHANGCHUN, CHINA and LOS ANGELES, CA--(eMediaWorld - December 2, 2008) - China Yongxin Pharmaceuticals, Inc. ("China Yongxin Pharmaceuticals" or "the Company") (OTCBB: CYXN), a leading distributor and retailer of pharmaceuticals in Northeastern China, announced today that it has recently established a Retailing Chain Management Head Office to uniformly manage its growing base of chain drugstores. "We established the Retailing Chain Management Head Office to further the implementation of our 5-year strategic development plan for the retailing chain business of China Yongxin," stated Mr. Yongxin Liu, Chairman and CEO of China Yongxin Pharmaceuticals, Inc. "This facility will allow us to plan for the expansion of the retailing chain through all levels, to integrate our resources and methodically execute on rolling out new stores. Concurrently, it will allow us to set up a standardized medicine retailin

Biotech REIT Blinks Back: Nearly $700 Million in Capital Construction Investment Is Halted, an Industrial Info News Alert

Tue, 02 Dec 2008 07:00:00 EST

SUGAR LAND, TX--(eMediaWorld - December 2, 2008) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Real estate investment trusts (REIT) have become increasingly attractive to the life science industry for the financial flexibility they can provide. Funds can be invested into increased research and other needs, rather than the "bricks and mortar" end of business. At the top of the REIT list, in both the public and private sector, is Alexandria Real Estate Equities (NYSE:ARE) (Pasadena, California).

Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients

Tue, 02 Dec 2008 01:14:00 EST

GENEVA, SWITZERLAND--(eMediaWorld - December 2, 2008) - Français (PDF): http://hugin.info/138017/R/1274456/283439.pdf Deutsch (PDF): http://hugin.info/138017/R/1274456/283440.pdf English (PDF): http://hugin.info/138017/R/1274456/283441.pdf Geneva, Switzerland, 2 December 2008 - Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. The standard dose of PPI does not control GERD adequately in about 40% of patients. ADX10059 is a first-in-class reflux inhibitor that works by selectiv

Kearny Ventures Hires Andrew Jensen as Chief Financial Officer

Mon, 01 Dec 2008 19:20:00 EST

SAN FRANCISCO, CA--(eMediaWorld - December 1, 2008) - Kearny Venture Partners has hired Andrew Jensen as Chief Financial Officer, the firm announced today. As CFO, Mr. Jensen will oversee investor relations, legal, finance, information technology and human resources, and he will assist the investing team with transaction structuring and financial due diligence. Prior to joining Kearny Ventures, Mr. Jensen was CFO of Liquid Realty Partners, a real-estate secondaries firm, from 2005 to 2008. Before that, he was the Senior Controller of Gryphon Investors and Director of Finance at Sanderling Ventures. Earlier, Mr. Jensen, a certified public accountant, was an audit manager with Arthur Andersen. He has earned his BA in Finance and Accounting with honors from the University of California, Berkeley.

Endo Announces Resignation of Board Member

Mon, 01 Dec 2008 16:30:00 EST

CHADDS FORD, PA--(eMediaWorld - December 1, 2008) - Endo Pharmaceuticals (NASDAQ: ENDP) announced today the resignation of George F. Horner, III as a member of the company's board of directors. Mr. Horner has been a director of Endo since August 2006 and has resigned to pursue other business opportunities. The resignation will be effective January 1st, 2009. "The board and I greatly appreciate George's contributions to Endo's growth and success and wish him well in his future endeavors," said David Holveck, president and chief executive officer of Endo.

Vanguard Pharmaceutical Corporation Negotiates Telomerase Delivery Technology

Mon, 01 Dec 2008 11:49:00 EST

SAN ANTONIO, TX--(eMediaWorld - December 1, 2008) - Vanguard Pharmaceutical Corp. (PINKSHEETS: VGPH), a company who has joined the fight against cancer by selling affordable generic oncology drugs and researching noninvasive cures for cancer, is now in negotiations with a biotechnology company who has an effective delivery method for telomerase therapies. Vanguard is negotiating to either acquire or gain a significant stake in the company.

Chembio Donates HIV Tests to Support World AIDS Day 2008 Testing Initiative

Mon, 01 Dec 2008 09:00:00 EST

MEDFORD, NY--(eMediaWorld - December 1, 2008) - Chembio Diagnostics, Inc. (OTCBB: CEMI) ("Chembio" or the "Company") joined AIDS Healthcare Foundation (AHF) in the World AIDS Day 2008 global effort to test one million people from November 26 through December 1, 2008. Based in Los Angeles, AHF provides state-of-the-art medicines and advocacy to over 85,000 people in 22 countries and is the nation's largest provider of HIV/AIDS medical care. Chembio is supporting these efforts by providing approximately 20,000 HIV 1/2 STAT-PAK® tests to testing programs in 3 countries. Chembio's HIV 1/2 STAT-PAK® and HIV 1/2 STAT-PAK® Dipstick tests are ideally suited for point-of-care testing with a simple test protocol, long shelf life, minimum sample requirements for venous or finger-stick whole-blood, plasma or serum, test results in < 10 minutes and room temperature storage requirements. Chembio has also complete

Prana Provides Update on Research and Development Programs at AGM

Mon, 01 Dec 2008 08:30:00 EST

MELBOURNE, AUSTRALIA--(eMediaWorld - December 1, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT) today provided an update of highlights of current and future activities of the Company at the Annual General Meeting. PBT2 for Alzheimer's Disease Chairman and CEO, Geoffrey Kempler, discussed the success of Prana's Phase IIa clinical trial of PBT2 in early Alzheimer's Disease and affirmed that the Company plans to enter larger clinical trials and advance towards commercialization.

Cleveland BioLabs Announces Appointment of International Expert in Chemical, Biological and Radiological/Nuclear Threat Countermeasures as Senior Vice President of Public Health and Government Services

Mon, 01 Dec 2008 08:18:00 EST

BUFFALO, NY--(eMediaWorld - December 1, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Michelle Ross, DVM, M.S, Ph.D., as Senior Vice President of Public Health and Government Services, with responsibility for commercialization of military and public health medical emergencies applications. Dr. Ross joins Cleveland BioLabs while remaining a Senior Partner for Biodefense and Public Health Programs with Martin, Blanck & Associates, a federal health services consulting firm.

Antisoma to present at Piper Jaffray Conference

Wed, 26 Nov 2008 11:55:00 EST

Antisoma to present at Piper Jaffray Annual Healthcare Conference in New York

GENEART receives major contract from the Wellcome Trust Sanger Institute

Wed, 26 Nov 2008 01:00:00 EST

REGENSBURG, GERMANY--(eMediaWorld - November 26, 2008) - - The Wellcome Trust Sanger Institute awards a major contract on synthesizing up to 600 genes over the next 10 months to GENEART - The supplied genes will be used in the research program of the Wellcome Trust Sanger Institute - The research program's goal is to identify mechanisms involved in defined genetic and infectious diseases Regensburg, November 26, 2008 - GENEART AG, world market leader for gene synthesis and specialist in Synthetic Biology, announces the closing of a major contract with the Wellcome Trust Sanger Institute, UK. GENEART will synthesize up to 600 tailor-made genes for the Wellcome Trust Sanger Institute's research program under this contract. The genes will be used to identify mechanisms involved in defined genetic and infectious disease. The terms of the agreement were not disclosed.

RxElite, Inc. and Minrad International, Inc. Terminate Distributor Agreement

Tue, 25 Nov 2008 12:21:00 EST

MERIDIAN, ID--(eMediaWorld - November 25, 2008) - RxElite, Inc. (OTCBB: RXEI) announced today that its manufacturing and distribution agreement with Minrad International, Inc. has been terminated. The termination of the manufacturing and distribution agreement allows RxElite to supply anesthetic gas products to its customers from alternative sources. RxElite will continue to supply products to its customers from existing inventory while working through supply arrangements from alternative sources. RxElite will work closely with its customers and vendors to ensure an ongoing supply of RxElite's key anesthetic gas products.

Are You One of the 260 Million Americans Who Needs Flu Vaccine?

Tue, 25 Nov 2008 11:00:00 EST

National Influenza Vaccination Week Is December 8-14

MediciGlobal Hosts Successful Recruitment and Retention Conference

Mon, 24 Nov 2008 15:18:00 EST

KING OF PRUSSIA, PA--(eMediaWorld - November 24, 2008) - MediciGlobal, a specialty patient recruitment and retention firm for adult and pediatric clinical trials, with a track record of success for over two decades, hosted a highly successful Patient Recruitment and Retention conference in Philadelphia, October 28-29, 2008 for the Jacob Fleming Group. The conference focused on new and innovative ways to reach patients, understanding key issues regarding patient recruitment in a global market, and the need to improve public perception of clinical trials.

Trinity Biotech Announces Success of Destiny Max Trials and First Orders From Japan

Mon, 24 Nov 2008 11:30:00 EST

DUBLIN, IRELAND--(eMediaWorld - November 24, 2008) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the success of the clinical trials for the Destiny Max and the first orders for Destiny Max from Kyowa Medex, its distributor in Japan. Clinical trials comparing the new high throughput Destiny Max haemostasis analyser with the Destiny Plus were recently successfully concluded by Trinity in three sites in the USA, Canada and Ireland. The instrument will be formally launched in Europe in the second week in December and a submission to the FDA will be filed simultaneously.

Real-Life Stories of Diabetes Success

Fri, 21 Nov 2008 16:49:00 EST

ALEXANDRIA, VA--(eMediaWorld - November 21, 2008) - How do you measure success? The December issue of Diabetes Forecast, the consumer magazine of the American Diabetes Association, features the personal triumphs of people with diabetes -- some of their stories may surprise you. Here are just a few: With a glucose meter tucked in his pocket, Jerry Nairn, 49, of Chandler, Arizona, completed his first marathon in 1998. Since then he has run a total of 44 marathons and two ultra-marathons despite having type 1 diabetes. A runner since junior high school, Nairn's passion for long distances has grown so much so that he runs between 30 and 50 miles per week and travels across the country to participate in marathons. "I'm more or less always training for a race," he says. "I think in general it helps keep me healthy."

Tecan's Infinite(R) M1000 and Infinite F500 Multimode Readers Are Certified as DLReady(TM)

Fri, 21 Nov 2008 11:50:00 EST

DURHAM, NC--(eMediaWorld - November 21, 2008) - Tecan, a global leader in laboratory automation and detection, has been granted DLReadyT certification status for its high-end multimode readers Infinite® M1000 and Infinite F500, by Promega Corporation, USA, a provider of innovative solutions and technical support to the life sciences industry. The multimode microplate readers have met Promega's acceptance criteria for being certified as DLReadyT in the corresponding validation program managed by Promega. The certification demonstrates compatibility with the Dual-Luciferase Assay and underlines the excellent injector and flash luminescence performance of Tecan's Infinite M1000 and Infinite F500 multimode microplate readers.

Media Advisory: Micronutrient Initiative Event to Commemorate Manufacture of the Five Billionth Vitamin A Capsule on Nov. 25 in Olds, Alberta

Thu, 20 Nov 2008 11:00:00 EST

CALGARY, ALBERTA--(eMediaWorld - Nov. 20, 2008) - The Micronutrient Initiative will mark an important milestone, the five billionth capsule of vitamin A manufactured for the Micronutrient Initiative in Canada at Banner Pharmacaps (Canada) Limited in Olds, Alberta. The Micronutrient Initiative's vitamin A program has saved the lives of more than two million children over the past 10 years. A global organization based in Ottawa, the Micronutrient Initiative is responsible for the procurement of millions of vitamin A supplements each year, which are distributed to children in 70 countries to help boost their immune systems.

Avis aux médias: L'Initiative pour les micronutriments va annoncer la fabrication de la cinq milliardième capsule de vitamine A le 25 novembre à Olds, Alberta

Thu, 20 Nov 2008 11:00:00 EST

CALGARY, ALBERTA--(eMediaWorld - 20 nov. 2008) - L'Initiative pour les micronutriments va bientôt marquer un jalon : la fabrication pour son compte, au Canada, de la cinq milliardième capsule de vitamine A par Banner Pharmacaps (Canada) Limited de Olds, Alberta. Au cours des 10 dernières années, le programme de vitamine A de l'Initiative pour les micronutriments a sauvé la vie de plus de deux millions d'enfants. Organisation mondiale basée à Ottawa, l'Initiative pour les micronutriments a la responsabilité de se procurer chaque année des millions de suppléments de vitamine A, qui sont distribués aux enfants de 70 pays afin d'aider à stimuler leur système immunitaire.

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on Telavancin for the Treatment of Complicated Skin and Skin Structure Infections

Wed, 19 Nov 2008 14:40:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - November 19, 2008) - Theravance, Inc. (NASDAQ: THRX) announced today that telavancin received a favorable recommendation from the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) for the proposed indication to treat complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). The Committee voted 21 to 5 that the data presented demonstrate the safety and effectiveness of telavancin for treatment of cSSSIs. The Committee also voted 18 to 5 (with 3 abstentions) that there are specific clinical situations in which the benefits of telavancin use in pregnant women with cSSSI would outweigh the risks, and 25 to 1 that a risk management strategy is needed to prevent unintended use of telavancin in pregnant women or women of

SRI Awarded National Institute on Drug Abuse Contract for Chemical Analysis of Opioid Peptides and Drugs of Abuse

Tue, 18 Nov 2008 11:30:00 EST

MENLO PARK, CA--(eMediaWorld - November 18, 2008) - SRI International, an independent, nonprofit research and development organization, announced today that it has been awarded a $1,788,011 contract by the National Institute on Drug Abuse (NIDA). The award is a continuation of two previous NIDA contracts for which SRI has provided chemical analysis of synthetic peptides and related compounds, as well as drugs of abuse. SRI's program will be managed by Kanthi Hettiarachchi, Ph.D., senior chemist in SRI's Biosciences Division.

American College of Physicians Finds No Substantial Differences Among "Second-Generation" Antidepressant Drugs

Tue, 18 Nov 2008 10:12:00 EST

New Guideline Looks at Effectiveness of Drugs Used to Treat Depressive Disorders

China West, LLC / China West II, LLC Arbitrations Against Genesis Pharmaceuticals Now Total $13.5 Million

Mon, 17 Nov 2008 11:01:00 EST

MIAMI, FL--(eMediaWorld - November 17, 2008) - China West has filed a second arbitration for $7.5 million USD against Genesis Pharmaceuticals (OTCBB: GNPH) for its breach of contract and failure to carry out its obligation under the Genesis Equity Partners operating agreement and contractual obligations. China West, LLC and China West II, LLC now have a total of $13.5 million in arbitration claims currently pending against Genesis Pharmaceuticals, Inc.

Endo Pharmaceuticals Announces Acceptance of UBS AG Settlement Offer Relating to Auction Rate Securities

Mon, 17 Nov 2008 08:49:00 EST

CHADDS FORD, PA--(eMediaWorld - November 17, 2008) - Endo Pharmaceuticals (NASDAQ: ENDP) announced today that it has accepted UBS AG's settlement offer relating to auction rate securities purchased by Endo from affiliates of UBS AG. Pursuant to the terms of the settlement offer, Endo Pharmaceuticals will be entitled to require UBS AG to purchase eligible auction rate securities for a price equal to original par value plus accrued but unpaid dividends or interest beginning on June 30, 2010 and ending on July 2, 2012. Endo Pharmaceuticals has also granted affiliates of UBS AG the sole discretion to sell or otherwise dispose of the eligible auction rate securities at any time until July 2, 2012, without prior notification to Endo Pharmaceuticals, so long as Endo Pharmaceuticals receives par value plus accrued but unpaid dividends or interest upon the sale. In addition, affiliates of UBS AG will make "no net cost" loans a

Cosmetic Patients: Are We Meeting Their Needs? Providing Optimal Satisfaction in Facial Rejuvenation

Fri, 14 Nov 2008 11:06:00 EST

OR-Live Webcast: November 17, 2008 6:00 PM EST

Corcept Therapeutics Announces Third Quarter 2008 Results

Thu, 13 Nov 2008 09:00:00 EST

MENLO PARK, CA--(eMediaWorld - November 13, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended September 30, 2008. For the third quarter of 2008, Corcept reported a net loss of $5.6 million, or $0.11 per share, compared to a net loss of $3.4 million, or $0.09 per share, for the third quarter of 2007. For the first nine months of 2008, the company reported a net loss of $13.9 million, or $0.30 per share, compared to a net loss of $7.4 million, or $0.23 per share, for the same period in 2007.

(AMEX: DXR) Daxor Corporation Announces Third Quarter 2008 Earnings

Thu, 13 Nov 2008 08:30:00 EST

NEW YORK, NY--(eMediaWorld - November 13, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced third quarter earnings for 2008. For the quarter ended September 30, 2008, total operating revenues increased by 29.1 % to $451,253 from $349,547 for the same period in 2007. This was mainly the result of one Blood Volume Analyzer being sold during the current quarter for $65,000 versus no Blood Volume Analyzers sold during the same period last year. During the current quarter, Volumex kit sales increased by $28,423 or 12.7% versus the same period in 2007.

DelSite Reports Third Quarter 2008 Results

Thu, 13 Nov 2008 08:29:00 EST

Completed and Planned Divestitures Will Further Company's Focus on Commercial Development of Vaccine, Drug Delivery and Adjuvant Technologies Conference Call Scheduled for 4:30 p.m. Eastern Today

What Obama's "Changes" Mean for Pharmaceutical Pricing: Cutting Edge Information Breaks Down What the Next Four Years May Hold

Thu, 13 Nov 2008 08:13:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - November 13, 2008) - During President Elect Obama's campaign there were many cries for change and none as loud as the cry for healthcare reform. Both candidates voiced their plans for change and the pharmaceutical industry must now focus on what an Obama presidency really means for their bottom line. Increasing the use of generic drugs for Medicare and Medicaid and allowing the importation of safe prescription drugs from other developed countries were two platforms on which the Obama health plan stood. A more costly proposition for pharma could be lifting the ban that currently prevents the federal government from negotiating with drug companies to get lower prices on drugs for the Medicare program. Obama's campaign estimated that this could cut government healthcare costs by $30 billion; money coming directly out of drug company's pockets.

Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue

Thu, 13 Nov 2008 08:10:00 EST

Novogen Limited's U.S. Subsidiary, Marshall Edwards, Inc. (Nasdaq: MSHL) Has Made the Following Announcement:

Antisoma to present at Lazard Capital Markets 5th Annual Healthcare Conference in New York

Thu, 13 Nov 2008 07:00:00 EST

LONDON and CAMBRIDGE, MA--(eMediaWorld - November 13, 2008) - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Director of Communications, Dr Daniel Elger, will be presenting at the Lazard Capital Markets healthcare conference in New York. The presentation is scheduled for 14:40 EST (19:40 GMT) on Tuesday, November 18th. A webcast of the presentation will be available to all on Antisoma's website at www.antisoma.com.

GENEART AG Publishes Final Numbers for the First Nine Months and the Third Quarter 2008

Thu, 13 Nov 2008 01:14:00 EST

REGENSBURG, GERMANY--(eMediaWorld - November 13, 2008) - - Net sales increase by more than 30 % to EUR 11.7M after nine months - Operating result of EUR 1.4M reached the previous year's level - Continued strong growth of small and mid-sized orders - Preliminary results are being confirmed Regensburg, November 13, 2008 - GENEART AG, global leader in gene synthesis and specialist in the field of Synthetic Biology, increased its net sales by more than 30 % from EUR 9.0M to EUR 11.7M over the first nine months compared to the previous year's reference period. The operating result (EBIT) reached EUR 1.4M and hence, the level of the prior year. Thereby GENEART confirms its preliminary results published recently.

Latest Research Has Medical Experts Considering New Testing Guidelines for Type 2 Diabetes Patients

Wed, 12 Nov 2008 17:38:00 EST

SAN DIEGO, CA--(eMediaWorld - November 12, 2008) - New research demonstrates that lowering post-meal blood sugar spikes after meals is critical to avoiding serious health complications for people concerned about managing their blood sugar, especially those diagnosed with Type 2 diabetes. As a result, medical experts are reconsidering when and how they advise Type 2 diabetes patients to test their blood sugar in order to best monitor the dangerous blood sugar spike zone that typically occurs 30 to 45 minutes after meals.

Chembio Reports Record Revenues in Third Quarter

Wed, 12 Nov 2008 16:42:00 EST

Highest Quarterly Revenues in Company History; Conference Call Scheduled for Wednesday, November 12 at 4:30 p.m. Eastern Time

MNI Nutraceuticals (MNIA) Spokesman Dr. Anthony Martin Featured in Morning Health Show on Major Television Network Now Available on YouTube.com

Wed, 12 Nov 2008 16:05:00 EST

RENO, NV--(eMediaWorld - November 12, 2008) - MNI Nutraceuticals Inc. (PINKSHEETS: MNIA) is pleased to announce that Dr. Martin's interview with popular morning health show on the CW network is now available for viewing on YouTube.com. Dr. Martin was invited on as a guest of Andrea Jackson, who is a host of the popular morning show The Daily Buzz, a nationally syndicated morning news program produced by ACME Communications which is aired on the CW Network -- which is a joint venture between CBS Corporation, and Warner Bros., a subsidiary of Time Warner. Dr. Martin took the opportunity to explain certain chapters of his new book, "Medical Crisis: Secrets Your Doctor Won't Share With You." Tony took the opportunity to speak about ways to better understand your body and how to make the environment surrounding you for a better health.

Disclosure of Shareholdings in Accordance with Stock Market Rules

Wed, 12 Nov 2008 01:20:00 EST

GENEVA--(eMediaWorld - November 12, 2008) - Addex Pharmaceuticals (SWISS: ADXN) announced today that on November 11, 2008, S.R. One Ltd, the investment arm of GlaxoSmithKline plc, informed of reaching the threshold of 5.0% in the shareholding of Addex Pharmaceuticals Ltd. as the result of its acquisition in the market of shares. S.R. One said it had acquired a total of 293,125 registered shares, corresponding to 5.0% of the voting rights.

AAIPharma Strengthens Global Clinical Development Services Unit With the Addition of Andreas Dreps Ph.D. and Ralf Wolter Ph.D.

Mon, 10 Nov 2008 23:00:00 EST

WILMINGTON, NC--(eMediaWorld - November 10, 2008) - AAIPharma, a global provider of drug development services, today announced the appointment of Andreas Dreps Ph.D. as Senior Vice President, Global Clinical Development Services. In addition, the company also announced that Ralf Wolter Ph.D. has joined as Vice President Clinical Operations - Europe reporting to Dr. Dreps. "We are very fortunate to add Andreas to the leadership team of the company," said Ludo Reynders Ph.D., CEO of AAI Pharma. "His vast drug development experience and track record, especially in the Clinical Oncology area, will be invaluable in the further development of our global clinical development business unit. As we organize our business around the customer, Andreas' scientific understanding and business acumen will provide great value to the customers and project teams we serve."

International Drug and Explosive Detection Firm IDenta Corp. Announces Five New Patent Applications -- Company's R&D Developing New Products That Will Generate Significant New Revenues

Mon, 10 Nov 2008 09:40:00 EST

JERUSALEM--(eMediaWorld - November 10, 2008) - IDenta Corp. (PINKSHEETS: IDTA) announced today that it is completing the submission of five new international patent applications for its drug precursor and explosive detection products. The new patents will add to the company's four existing patents for cocaine and crack detection, heroin detection, ecstasy detection and its patent for chemical detection product packaging. "These new patents will add significant book value to the company's assets," asserted Yaacov Shoham, IDTA CEO. "Each new product addresses either a critical new need, such as drug precursors, or is an important refinement to existing drug detection products. There is great demand for each of these new IDenta products, and we believe that in the coming years they will add significant revenue and profits to our bottom line."

Novo Nordisk Launches Levemir(R) Satisfaction Guarantee Program

Mon, 10 Nov 2008 09:00:00 EST

Satisfied or Their Money Back

GENEART Successfully Concludes Project to Complete the National Institutes of Health's "Mammalian Gene Collection"

Mon, 10 Nov 2008 07:05:00 EST

REGENSBURG, GERMANY--(eMediaWorld - November 10, 2008) - - Historic event: "Mammalian Gene Collection" completed - For the project GENEART synthesized approx. 2,400 genes - Additional growth impulses expected for the gene synthesis market Regensburg, November 10, 2008 - GENEART AG, global leader in gene synthesis and specialist in the field of Synthetic Biology, announces the successful conclusion of its project with the US National Cancer Institute (part of the National Institutes of Health) in regard to the "Mammalian Gene Collection" (MGC) today.

Delcath Systems to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference

Fri, 07 Nov 2008 10:57:00 EST

NEW YORK, NY--(eMediaWorld - November 7, 2008) - Delcath Systems (NASDAQ: DCTH), a leading developer of regional therapy for cancer, announced today that their President and CEO, Richard Taney, will present at the Rodman & Renshaw 10th Annual Global Healthcare Conference in New York City on Monday, November 10, 2008 at 3:15 PM EST. The conference will be held at the New York Palace Hotel. About Delcath Systems, Inc. Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of

New Options for Advanced Heart Disease

Thu, 06 Nov 2008 14:50:00 EST

OR-Live Webcast From Montefiore-Einstein Heart Center November 13, 2008 7:00 PM EST

GENEART AG Publishes Preliminary Figures for Q3 2008

Thu, 06 Nov 2008 01:20:00 EST

REGENSBURG, GERMANY--(eMediaWorld - November 6, 2008) - - Net sales for 2008 at EUR 11.7M after 9 months - EBIT reaches EUR 1.4M - For the entire year of 2008, net sales between EUR 15.5M and 16.5M are expected with EBIT at prior year's level - Market position was further expanded in slightly weaker market conditions Regensburg, November 6, 2008 - GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology, reached net sales of EUR 11.7M (preliminary figures) during the first nine months of 2008. This exceeds prior year's net sales figures of EUR 9.0M for the reference period by 30 %. The operating result (EBIT) totaled EUR 1.4M after nine months and was therefore at previous year's levels.

CLSI Publishes Guideline for Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters

Tue, 04 Nov 2008 11:05:00 EST

WAYNE, PA--(eMediaWorld - November 4, 2008) - Clinical and Laboratory Standards Institute (CLSI) is responsible for the development of standardized reference methods for in vitro tests that measure the susceptibility of bacteria to antimicrobial agents. CLSI has recently published an updated document, "Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline--Third Edition (M23-A3)," which is a key foundation document in CLSI's widely used "family" of susceptibility testing documents. Data developed according to this guideline are the basis for establishing interpretive and quality control (QC) criteria for CLSI antimicrobial susceptibility testing standards.

IBC's 3rd International Conference; ACCESS India & China

Tue, 04 Nov 2008 11:00:00 EST

WESTBOROUGH, MA--(eMediaWorld - November 4, 2008) - IBC Life Sciences has announced that the ACCESS India & China international conference will take place at the Sheraton Hotel & Marina, in San Diego, California on February 9-10, 2009. As the Asia partnering landscape is rapidly changing, ACCESS India & China helps to uncover not just the capabilities of Asian partners, but also any potential gaps in preclinical sourcing and inventory resources, along with techniques to overcome them. Formerly titled "Biology, Preclinical and Beyond in India and China," this year's conference focuses on examples of partnerships where companies were able to combine resources, increase capacity, gain speed and find new ideas.

OctoPlus to present at Rodman and Renshaw conference

Tue, 04 Nov 2008 01:45:00 EST

LEIDEN, NETHERLANDS--(eMediaWorld - November 4, 2008) - OctoPlus N.V. (Euronext: OCTO), the drug delivery company, announces today that its CEO will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York next week. Simon Sturge, Chief Executive Officer, will present on Wednesday 12 November at 4:55 PM EDT. For further information, please contact: Rianne Roukema, Corporate Communications, telephone number +31 (71) 524 1071 or e-mail IR@octoplus.nl.

Pronova BioPharma appoints Per-Oluf Olsen as new CEO

Tue, 04 Nov 2008 01:10:00 EST

LYSAKER, NORWAY--(eMediaWorld - November 4, 2008) - Pronova BioPharma ASA (OSE: PRON.OL) announced today that the board of directors has appointed Per-Oluf Olsen as chief executive officer to succeed Tomas Settevik, who has informed the board that he wishes to stand down from his position as CEO. Per-Oluf Olsen, aged 52, will assume the role of CEO with effect from 17 November 2008. He joins Pronova BioPharma after 27 years with Pfizer Inc., where he gained extensive international experience in sales, marketing and management. Most recently, Mr. Olsen was regional executive director for Central and Eastern European region, inclusive regional office in Brussels. He was previously country manager for Pfizer in Italy, Norway and Denmark and has held a number of senior sales and marketing positions for the company in Norway and the USA.

International Drug & Explosives Detection Firm IDenta, Releases 2008 Year to Date Revenues -- Forecasts Three-Fold Increase in 2009

Mon, 03 Nov 2008 09:40:00 EST

JERUSALEM--(eMediaWorld - November 3, 2008) - IDenta Corp. (PINKSHEETS: IDTA) today released its revenues figures for the first 10 months of 2008. The company reported revenues of $397,681 for the period of January through October. Company executives also project that IDenta is on track to finish the year with nearly $500,000 in revenues. "Investors with long-term interests can be sure that IDenta's revenues are in a position to grow exponentially in 2009," predicted Yaacov Shoham, IDTA CEO. "We now have a strong base of law enforcement accounts around the world that the company can count on each month for repeat sales. As we move into 2009 the majority of these revenues will continue and new sales will just add more revenues to this repeating sales cycle. In 2009 IDenta expects to add new markets, in east and south east Asia, in Europe etc.

Operating results for Solvay Group (EUR 840 million) down by 9% compared to the excellent results of the first nine months 2007 - Good resistance in the third quarter (-6%)

Thu, 30 Oct 2008 02:28:00 EDT

BRUSSELS, BELGIUM--(eMediaWorld - October 30, 2008) - The full press release is available on http://www.solvay-investors.com/ EMBARGO: Brussels, October 30, 2008 at 7:30 AM REGULATED INFORMATION Operating results for Solvay Group (EUR 840 million) down by 9% compared to the excellent results of the first nine months 2007 Good resistance in the third quarter (-6%) - Sales (EUR 7,217 million) stable (+3% at constant exchange rates) for the first 9 months and up by 4% in the third quarter

Hospitals Nationwide Adopt Breakthrough I.V. Dose Preparation Technology to Improve Patient Safety and Reduce Costs

Wed, 29 Oct 2008 09:29:00 EDT

Citing Rising Demand for IV Room Automation Systems and Increasing Component Costs, ForHealth Technologies Increases Pricing for IntelliFill i.v. Effective December 1, 2008

Antisoma appoints Eric Dodd as Chief Financial Officer

Tue, 28 Oct 2008 08:31:00 EDT

LONDON and CAMBRIDGE, MA--(eMediaWorld - October 28, 2008) - London, UK, and Cambridge, MA: 28 October 2008: Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that Eric Dodd has been appointed as Chief Financial Officer with effect from November 3rd 2008 and that he will join the Antisoma Board as an Executive Director. Mr Dodd, 39, has extensive experience in technology businesses. He was previously Group Finance Director at Morse plc, a consulting, IT services and technology company. Before joining Morse in 2005, he held management positions at a number of companies, including GlaxoSmithKline, where he worked in the UK pharmaceuticals business. Mr Dodd qualified as an accountant with Deloitte and holds an MBA from London Business School.

Ophthotech Enrolls First Patient in a Phase I Complement (Anti-C5) Inhibitor Trial for Macular Degeneration

Mon, 27 Oct 2008 07:01:00 EDT

ARC1905 Represents Second Compound in Clinical Development

Bilcare GCS Expands Global Distribution and Warehousing Network

Fri, 24 Oct 2008 10:14:00 EDT

PHOENIXVILLE, PA--(eMediaWorld - October 24, 2008) - Furthering its commitment to satisfying a worldwide customer base, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has substantially expanded its global distribution and warehousing capabilities for clinical trial supplies. Bilcare GCS has formalized its working relationship by signing a service agreement with World Courier to utilize depots in Argentina, Brazil, Colombia, Chile, Mexico, Peru, and Russia. The new locations supplement Bilcare's existing network with locations in India, U.K., Singapore and the United States. Additional global depot locations are planned for the near future.

Genealogy Testing Company Looks to REMP and Tecan for Automated Sample Management

Fri, 24 Oct 2008 09:28:00 EDT

DURHAM, NC--(eMediaWorld - October 24, 2008) - Scientists at Family Tree DNA, Texas, USA, have automated their DNA testing services using a REMP Small-Size StoreT (SSS) and a Tecan Freedom EVO® liquid handling workstation to reliably process and store the hundreds of samples arriving daily. Family Tree DNA provides genealogy services on request for customers worldwide, using PCR-based technologies in about 150 different genetic tests to establish relatedness of DNA samples. "We investigated several sample management systems," said Dr Thomas Krahn, Lab Manager of the Family Tree DNA Genomics Research Center in Houston, "and chose the REMP technology because it was the most efficient. We are very happy with the system."

GENEART again among Germany's Top "Technology Fast 50" Companies

Thu, 23 Oct 2008 07:37:00 EDT

REGENSBURG, GERMANY--(eMediaWorld - October 23, 2008) - - GENEART among the top 15 of the fastest growing technology companies in Germany - Among life science companies of this competition, GENEART ranks second - Cumulative corporate growth exceeds 800 percent over the past five years - Targeted investing in automation and process technologies allows further increase in capacities Regensburg, October 23, 2008 - Above average growth in net sales earns GENEART No. 11 ranking in Deloitte's "Technology Fast 50" award of the fastest growing technology companies in Germany. The 50 winners of the growth prize awarded by audit and business consulting service provider Deloitte presented themselves in Dusseldorf last night. Rankings are based on cumulative net sales growth in percent over the past five years. GENEART, publicly traded global leader in gene synthesis and specialist in the field of Synthetic Biology, lif

InfoMedics Launches Adherence Driver(TM), the First Targeted, Brand-Specific Patient Adherence Solution

Tue, 21 Oct 2008 09:10:00 EDT

InfoMedics to Demonstrate Program at 5th Annual Patient Adherence & Persistence Summit USA, October 23-24, Boston, MA; Chief Medical Officer Dr. Stanley Wulf to Give Solo and Panel Presentations About Adherence

Stem Cell Therapeutics Corp. Invited to Present at Florida's Largest Bioscience Forum

Mon, 20 Oct 2008 10:43:00 EDT

CALGARY, ALBERTA--(eMediaWorld - Oct. 20, 2008) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announces today Dr. Alan Moore, President and CEO, will be participating in a panel discussion at BioFlorida's 11th Annual Conference to be held October 19-21 at the Ritz-Carlton in Amelia Island, Florida. The panel discussion, titled "Individualized Medicine", will be chaired by Dr. Todd E. Golde, Professor and Consultant in the Department of Neuroscience at the Mayo Clinic Jacksonville. In addition to Dr. Moore, the panel includes Dr. Daniel Kelly, Scientific Director and Professor at the Burnham Institute for Medical Research and Dr. Dennis Steindler, Professor of Neuroscience and Neurosurgery at the University of Florida, College of Medicine.

NAOMI Study: Results Show That North America's First Heroin Therapy Study Keeps Patients in Treatment, Improves Their Health and Reduces Illegal Activity

Fri, 17 Oct 2008 11:45:00 EDT

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Oct. 17, 2008) - Researchers from the North American Opiate Medication Initiative (NAOMI Study) today released final data on the primary outcomes from the three-year randomized controlled clinical trial. "Our data show remarkable retention rates and significant improvements in illicit heroin use, illegal activity and health for participants receiving injection assisted therapy, as well as those assigned to optimized methadone maintenance," says Dr. Martin Schechter, NAOMI's Principal Investigator, Centre for Health Evaluation and Outcome Sciences and Professor and Director, University of British Columbia School of Population and Public Health. "Prior to NAOMI, all of the study participants had not benefited from repeated standard addiction treatments. Society had basically written them off as impossible to treat."

DSP Clinical Research Named to Inc. 500

Fri, 17 Oct 2008 09:28:00 EDT

PARSIPPANY, NJ--(eMediaWorld - October 17, 2008) - DSP Clinical Research announced today that Inc. Magazine named the boutique clinical research organization 220th on its 2008 Inc. 500 list. It is the first time that DSP has been named an Inc. 500 company. Inc. Magazine reported DSP's three-year revenue growth at 1,143.7% to $6.9 million. DSP Clinical Research was formed in 1999. The privately held company focuses on providing turnkey clinical research services to small to midsize pharmaceutical and biotechnology companies that have limited internal infrastructure to initiate, manage, and monitor Phase I-IV clinical development programs.

Catholic Hospice Selects OnePoint Patient Care as Its Exclusive Provider of Hospice Pharmacy Services

Fri, 17 Oct 2008 09:04:00 EDT

OnePoint to Provide Clinical Expertise, Custom Compounding and Prompt, Local Deliveries to Catholic Hospice's Florida Patients

NAOMI Study: Media Advisory; Researchers to Present Results From North America's First Clinical Trial of Medically Prescribed Heroin Therapy

Fri, 17 Oct 2008 08:00:00 EDT

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Oct. 17, 2008) - Researchers from the North American Opiate Medication Initiative (NAOMI Study) will host a news conference today at St. Paul's Hospital to share study data. /T/ What: Researchers will present final results of the primary outcomes data from the NAOMI Study - a three-year randomized controlled clinical trial comparing prescribed heroin to optimized methadone for people with chronic heroin addiction. NAOMI researchers will

Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa

Fri, 17 Oct 2008 00:51:00 EDT

LEIDEN, NETHERLANDS and PARIS--(eMediaWorld - October 17, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) and the Aeras Global TB Vaccine Foundation today announce the start of a Phase I clinical trial in Kenya of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35. The announcement is made in the lead up to the 39th Union World Conference on Tuberculosis and Lung Disease in Paris, France (16-20 October, 2008).

NAOMI Study: Media Advisory; Researchers to Present Results From North America's First Clinical Trial of Medically Prescribed Heroin Therapy

Thu, 16 Oct 2008 10:30:00 EDT

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Oct. 16, 2008) - Researchers from the North American Opiate Medication Initiative (NAOMI Study) will host a news conference at St. Paul's Hospital on Friday, October 17 to share study data. What: Researchers will present final results of the primary outcomes data from the NAOMI Study - a three-year randomized controlled clinical trial comparing prescribed heroin to optimized methadone for people with chronic heroin addiction. NAOMI researchers will be available for questions and interviews following the news conference.

PharmaCom BioVet, Inc. Introduces Novel Cancer Treatments in Partnership With IsoTherapeutics Group

Wed, 15 Oct 2008 07:41:00 EDT

RALEIGH, NC--(eMediaWorld - October 15, 2008) - PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce they have entered into a collaborative agreement with IsoTherapeutics Group (ITG) to co-develop and introduce novel therapeutic treatments for companion animals. With a special interest in radiopharmaceuticals for oncology, ITG focuses on the development of technologies aiding in the diagnosis and treatment of debilitating diseases such as cancer.

BioCurex Update Following the 2008 ISOBM Congress. RECAF Triggers Interest for Multiple Collaborations

Wed, 15 Oct 2008 07:30:00 EDT

RICHMOND, BRITISH COLUMBIA--(eMediaWorld - Oct. 15, 2008) - BioCurex Inc. (OTCBB:BOCX) - wishes to update its shareholders on its participation in the international annual meeting of the International Society for Oncology and Bio-Markers (ISOBM). The Company was represented by Dr. Moro, who did two presentations: One related to the advent of its new RECAF-ELISA, the most popular format for immunoassays in most clinical and research laboratories. In the other presentation, Dr. Moro overviewed the RECAF cancer marker biology and presented results obtained in the Company's lab as well as from collaborations with other laboratories. The presentation focused on gastrointestinal cancers and it included results obtained with radio-immunoassay (RIA), chemiluminescence (CIA) and enzyme-immunoassay (ELISA). The recently announced results obtained with saliva samples triggered the interest of the session participants.

Cutting Edge Information Study Finds That External Market Factors Are Top Cause of Deal Failures

Wed, 15 Oct 2008 07:18:00 EDT

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - October 15, 2008) - New research explores the top reasons that pharmaceutical deals fail and offers solutions to prevent agreements from collapsing. According to the study, "Pharmaceutical Alliance Management," 43% of pharmaceutical companies have had a deal fail due to market factors outside of their control (www.PharmaDealMaking.com). Whereas the top two reasons for deal failure -- external market factors and unfavorable scientific findings -- are largely out of the hands of partner companies, almost every other reason for unsuccessful deals can be directly or indirectly tied to alliance management. For example, another top reason for deal failure is that unrealistic goals are set by one or both partners. This and other causes of deal failure are best addressed through meticulous alliance management, according to the study.

Basilea's Toctino(R) (alitretinoin) receives marketing authorization in Finland

Wed, 15 Oct 2008 00:16:00 EDT

BASEL, SWITZERLAND--(eMediaWorld - October 15, 2008) - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM). Following the recommendation for regulatory approval under the European decentralized procedure, Toctino® received national regulatory approval in Finland. Following the regulatory approval of Toctino® in Finland, Basilea will submit a pricing and reimbursement dossier to the Finnish authorities.

Addex Parkinson's Product Progressing in Early Clinical Trials

Wed, 15 Oct 2008 00:06:00 EDT

GENEVA, SWITZERLAND--(eMediaWorld - October 15, 2008) - Français (PDF): http://hugin.info/138017/R/1259601/275525.pdf Deutsch (PDF): http://hugin.info/138017/R/1259601/275514.pdf English (PDF): http://hugin.info/138017/R/1259601/275461.pdf Geneva, Switzerland, 15 October 2008 - Addex Pharmaceuticals (SWX: ADXN) announced that it has completed the first part of a two-part Phase I clinical trial to evaluate the newly developed modified release formulation of ADX48621. ADX48621 is scheduled to start a Phase IIa proof of concept study for the treatment of levodopa associated dyskinesia in Parkinson's disease during the first half of 2009.

ONI BioPharma Inc. Announces Successful Antibiotic Synthesis Using DPOLT(TM) Technology

Tue, 14 Oct 2008 15:30:00 EDT

ALACHUA, FL--(eMediaWorld - October 14, 2008) - ONI BioPharma Inc. (AMEX: ONI) announced today the successful synthesis of an antibiotic using its proprietary DPOLT technology. The molecule belongs to a class of antibiotics called Lantibiotics that were first discovered over 80 years ago. Although there are now over 50 different Lantibiotics known, this is the first report of a cost-effective method for making one in sufficient quantities and with sufficient purity to enable comprehensive testing and commercial viability.

Santhera Launches CATENA(R) in Canada

Fri, 10 Oct 2008 08:28:00 EDT

LIESTAL, SWITZERLAND--(eMediaWorld - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada. The drug is indicated for the treatment of Friedreich's Ataxia, a rare neuromuscular disease that results in the degeneration of nerve and muscle tissue. Catena is the first and only approved therapy in Canada to treat this devastating genetic disorder. Santhera estimates that there are a few hundred Friedreich's Ataxia patients in Canada, where the prevalence ranks among the highest concentrations in North America. The Company is working with physicians, patient advocacy groups, government agencies and insurance companies in order to quickly provide Catena to the patients. First prescriptions are being processed.

Santhera lance CATENA(R) au Canada

Fri, 10 Oct 2008 08:28:00 EDT

LIESTAL, SUISSE--(eMediaWorld - 10 oct. 2008) - Santhera Pharmaceuticals (SWX:SANN), une compagnie pharmaceutique suisse spécialisée dans le traitement des maladies neuromusculaires, a annoncé aujourd'hui le lancement de CATENA(R) (idébénone) au Canada. Le médicament est indiqué pour le traitement de l'ataxie de Friedreich, une maladie neuromusculaire rare qui entraîne la dégénérescence du système nerveux et des tissus musculaires. Catena est le premier et le seul médicament approuvé au Canada pour traiter cette maladie génétique dévastatrice. Santhera estime que le nombre de patients au Canada atteints de l'ataxie de Friedreich s'élève à quelques centaines de personnes, avec une concentration plus élevée dans la province du Québec, où l'on note l'une des incidences les plus élevées en Amérique du Nord. La compagnie travaille avec des médecins, des groupes de défense des droits des patients, des agences gouvernementales et des compagnies d'assurance pour être en mesure d'offrir Catena a

SOHM, Inc. Focuses on Manufacturing Agreements and Acquisitions Within India's Pharmaceutical Sector

Fri, 10 Oct 2008 08:20:00 EDT

Exports From India Operations to Emerging Markets in Africa, Latin America, and Southeast Asia Expected to Be Strong

Learn About The Future of RNAi Therapeutics: Drug Pipelines and Prospects

Thu, 09 Oct 2008 09:38:00 EDT

LONDON, UNITED KINGDOM--(eMediaWorld - Oct. 9, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. The Future of RNAi Therapeutics: Drug Pipelines and Prospects http://www.reportlinker.com/p096060/The-Future-of-RNAi-Therapeutics-Drug-Pipelines-and-Prospects.html

GENEART Reaches Contest Final "Entrepreneur of the Year 2008"

Thu, 09 Oct 2008 03:01:00 EDT

REGENSBURG, GERMANY--(eMediaWorld - October 9, 2008) - - Ernst & Young honours Germany's best mid-tier companies - Impressive growth rates and high innovative strength lead GENEART AG's team into the final - Prestigious business award will be presented at the Alte Oper Frankfurt on October 9, 2008. Regensburg, October 08, 2008 -GENEART AG, world market leader for gene synthesis and expert in Synthetic Biology has reached the "Entrepreneur of the Year 2008"-final for the second consecutive time. This award honours entrepreneurial top performances, and only Germany's most innovative companies with the strongest growth numbers reach the final.

Medivisor, Inc. Featured in Profile at WallStreetResearch.org

Tue, 07 Oct 2008 07:45:00 EDT

HUNTINGTON STATION, NY--(eMediaWorld - October 7, 2008) - Medivisor, Inc. (PINKSHEETS: MVSR), developer of next-generation focus driven marketing tools, announced today that it has been featured in a corporate profile posted at www.wallstreetresearch.org. WallStreet Research specializes in the microcap and smallcap arena, looking for emerging growth companies with strong management, unique proprietary technology, creative marketing, significant market potential, value, financial strength and outstanding long-term earnings growth.

Antisoma and The Institute of Cancer Research to collaborate on novel approach to cancer treatment

Tue, 07 Oct 2008 01:07:00 EDT

LONDON and CAMBRIDGE, MA--(eMediaWorld - October 7, 2008) - Cancer drug developer Antisoma (LSE: ASM; USOTC: ATSMY), The Institute of Cancer Research (The Institute) and Cancer Research Technology (CRT) today announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialise novel anti-cancer compounds called PPM1D (protein phosphatase magnesium-dependent 1 d) inhibitors.

Learn about the Global Clinical Trial Business Report and Analysis 2008-2018

Mon, 06 Oct 2008 09:33:00 EDT

LONDON, UNITED KINGDOM--(eMediaWorld - Oct. 6, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Global Clinical Trial Business Report and Analysis 2008-2018 http://www.reportlinker.com/p096395/Global-Clinical-Trial-Business-Report-and-Analysis-2008-2018.html

Examine the Inflammatory Bowel Disease Market-Convenience and compliance drive market success

Mon, 06 Oct 2008 09:17:00 EDT

LONDON, UNITED KINGDOM--(eMediaWorld - Oct. 6, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success http://www.reportlinker.com/p095770/Commercial-Insight-Inflammatory-Bowel-Disease---Convenience-and-compliance-drive-market-success.html

Learn about the Production, market and benchmarking of Carnitine in China

Mon, 06 Oct 2008 08:54:00 EDT

LONDON, UNITED KINGDOM--(eMediaWorld - Oct. 6, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Production, market and benchmarking of Carnitine in China http://www.reportlinker.com/p096340/Production-market-and-benchmarking-of-Carnitine-in-China.html

Novacea, Inc. and Transcept Pharmaceuticals, Inc. Announce Filing of Form S-4 Proxy/Registration Statement

Mon, 06 Oct 2008 07:30:00 EDT

SOUTH SAN FRANCISCO, CA and POINT RICHMOND, CA--(eMediaWorld - October 6, 2008) - Novacea, Inc. (NASDAQ: NOVC) and Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that on October 3, 2008, Novacea filed its Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its proposed merger with Transcept. The definitive merger agreement was entered into on August 29, 2008.

Medivisor, Inc. Announces Exclusive Distribution Rights in Korea for Albumax

Mon, 06 Oct 2008 07:15:00 EDT

HUNTINGTON STATION, NY--(eMediaWorld - October 6, 2008) - Medivisor, Inc. (PINKSHEETS: MVSR), developer of next-generation focus driven marketing tools, announced today that it has expanded its previously announced Albumax marketing agreement. Medivisor has expanded its original agreement covering US distribution and Medivisor now has the exclusive right to distribute Albumax in Korea. Albumax, a whey protein isolate formula, makes it easy for Kidney disorder patients to reach their daily requirements of high quality protein in their diet. Medivisor anticipates consummating a distribution relationship in Korea shortly.

Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US

Wed, 01 Oct 2008 14:39:00 EDT

Additional Milestone Achieved in Collaboration Agreement with sanofi pasteur

Examine the World Intranasal Drug Delivery Market

Wed, 01 Oct 2008 14:09:00 EDT

LONDON, UNITED KINGDOM--(eMediaWorld - Oct. 1, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. World Intranasal Drug Delivery Market http://www.reportlinker.com/p092577/World-Intranasal-Drug-Delivery-Market.html

The GENEART AG Presents its Work at the Most Important International Conference on Synthetic Biology in Hong Kong

Wed, 01 Oct 2008 04:01:00 EDT

REGENSBURG, GERMANY--(eMediaWorld - October 1, 2008) - - GENEART presents the advantages of designed genes and gene synthesis in the programming of vaccines - GENEART will chair an "Industrial Biotechnology" workshop - 'Synthetic Biology 4.0' is the most important international conference on Synthetic Biology, now in its fourth year - GENEART is one of the main sponsors - With DNA synthesis, GENEART provides one of the key technologies for the Synthetic Biology

CRGP Seeks $13 Million Arbitration Against GTEC

Tue, 30 Sep 2008 15:05:00 EDT

Capital Research Group Measures Potential Shareholder Claim

PGA Tour Professional Says Natural Joint Supplement Saved His Career

Tue, 30 Sep 2008 14:52:00 EDT

Professional Golfer Fuzzy Zoeller Struggled With Potentially Career Ending Joint Pain Until He Discovered Conquer HA(R) Natural Hyaluronic Acid Formula

New Breathe Again(TM) Seawater Saline Nasal Spray Now Available in the United States

Fri, 26 Sep 2008 10:38:00 EDT

Seawater Nasal Spray Helps During Fall Allergy, Cold and Flu Season

BASi Appoints New Vice President of Sales & Marketing

Fri, 26 Sep 2008 10:35:00 EDT

WEST LAFAYETTE, IN--(eMediaWorld - September 26, 2008) - BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) has named Jon Brewer as Vice President - Sales and Marketing effective October 1, 2008. He replaces Emilio Córdova who has resigned from BASi to pursue other opportunities. Mr. Brewer has nearly 25 years of experience as a sales and marketing executive in the pharmaceutical industry. Most recently he consulted with companies to develop and implement new business strategies. Prior to that he served as Vice President of Integrity Pharmaceuticals and continued in this role through the merger with Xanodyne, a specialty pharmaceutical company headquartered in Cincinnati, Ohio. He has a strong history of developing and executing product launches and sales strategies resulting in exceptional sales growth.

OnePoint Patient Care Expands Into Larger Nevada Facility in Response to Growing Demand From Its Hospice Partners

Fri, 26 Sep 2008 08:30:00 EDT

New Facility's Expanded Space, Central Location Allow OnePoint to Enhance the Level of Comfort and Care Its Hospice Partners Can Provide Their Patients

Disclosure of Shareholdings in Accordance With Stock Market Rules

Fri, 26 Sep 2008 08:08:00 EDT

GENEVA--(eMediaWorld - September 26, 2008) - Addex Pharmaceuticals (SWISS: ADXN) announced today that on September 25, 2008, S.R. One Ltd, the investment arm of GlaxoSmithKline plc, has informed of reaching the threshold of 3.0% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 175,951 registered shares, corresponding to 3.0% of the voting rights. About Addex Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that we believe will offer patients better results than classical drugs. Most marketed drugs bind receptors where the body's own natural molecular activators (i.e. endogenous ligands) bind, specifically to a key part of each receptor's anatomy called the "active site". In short, most drugs must out-compete endogenous ligands fo

Thallion Enrolls First Patient in TLN-4601 Phase II Trial

Thu, 25 Sep 2008 15:01:00 EDT

Receives FDA approval to initiate TLN-4601 trial in U.S.

Thallion recrute un premier patient pour un essai de Phase II évaluant TLN-4601

Thu, 25 Sep 2008 15:01:00 EDT

La Société reçoit l'approbation de la FDA afin de débuter un essai clinique pour TLN-4601 aux Etats-Unis

American Diabetes Association Celebrates Historic Victory for Americans With Disabilities

Thu, 25 Sep 2008 11:00:00 EDT

President Bush Signs Landmark Civil Rights Legislation Into Law

Albumax Has Been Approved by Medicaid in California & Pennsylvania

Thu, 25 Sep 2008 08:00:00 EDT

HUNTINGTON STATION, NY--(eMediaWorld - September 25, 2008) - Medivisor, Inc. (PINKSHEETS: MVSR) announced today that Albumax has been approved by the California and the Pennsylvania State Medicaid Offices. Albumax has previously received approval from the New York State Medicaid Office. Albumax has been approved under code B4155 as an enteral product. This approval allows for Medicaid reimbursement of costs for eligible patients using Albumax. Medicaid is the largest source of funding for medical and health-related services for people with limited income. It is an entitlement program that is jointly funded by the states and federal government, and is managed by the states. Among the groups of people served by Medicaid are eligible low-income parents, children, seniors, and people with disabilities.

GlobeImmune Announces Late-Breaker Presentation of Interim Efficacy and Safety Data for GI-5005 at AASLD 2008 Meeting

Wed, 24 Sep 2008 12:00:00 EDT

LOUISVILLE, CO--(eMediaWorld - September 24, 2008) - GlobeImmune, Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2008, in San Francisco. The abstract, titled "GI-5005 Immunotherapy Plus Peg-IFN/Ribavirin In Genotype 1 Chronic Hepatitis C Patients Compared to Peg-IFN/Ribavirin Alone in Naïve and Non-Responder Patients; Preliminary RVR and Viral Kinetic Analysis from the GI-5005-02 Phase 2 Study," was published online today by the AASLD.

Medivisor, Inc. Receives Initial Purchase Order

Wed, 24 Sep 2008 07:30:00 EDT

HUNTINGTON STATION, NY--(eMediaWorld - September 24, 2008) - Medivisor, Inc. (PINKSHEETS: MVSR) developer of next-generation, focus driven marketing tools primarily for pharmaceutical companies, is pleased to announce that it has received a purchase order for Albumax from Critical Healthcare Solutions, Inc. for their East Goshen Pharmacy Inc. unit. "After completing our sales and marketing agreement for Albumax just a few weeks ago, our initial marketing efforts are already starting to pay off. We are already beginning to see a strong interest in the product, have received Medicaid approval in New York, and are pleased to announce this initial purchase order for Albumax in such a short period of time," stated Dino Luzzi, CEO of Medivisor, Inc. "Our marketing efforts are just getting underway and as we continue to bring awareness of Albumax to the marketplace, we anticipate further purchase order announcements,"

ImmuneRegen Scientist to Present Viprovex(R) Pre-Clinical Study Findings at 2008 BARDA Industry Day

Wed, 24 Sep 2008 05:30:00 EDT

Drug Candidate Shown to Enhance the Safety and Efficacy of Tamiflu(R) for Treatment of Influenza

Neotropix Appoints Anthony Williams, M.D., as Its Chief Medical Officer

Tue, 23 Sep 2008 07:01:00 EDT

MALVERN, PA--(eMediaWorld - September 23, 2008) - NeotropixT, Inc., a clinical-stage development company focused in neuroendocrine cancer treatments, today announced the appointment of Anthony Williams, M.D., as its Chief Medical Officer (CMO). Dr. Williams has more than 25 years of drug development experience, working for major pharmaceutical and biotechnology companies including GlaxoSmithKline, Merrell Dow and Dyax Corporation. In this new role as CMO, Dr. Williams is the most senior physician of the company with primary responsibility for patient safety, general medical governance, ethics and integrity, medical information and investigations involving human subjects relating to Neotropix's anti-cancer products in clinical development.

REMINDER: ORLive Presents: Improved Operative Outcomes in Open Hysterectomy

Tue, 23 Sep 2008 06:15:00 EDT

Live Webcast: From Inova Fairfax Hospital Women's Center: September 23, 2008 - 7:00 PM EDT (23:00 UTC) - 7:00 PM PDT (02:00 UTC) - 18:00 CEST (16:00 UTC)

UNC Charlotte to Evaluate Potential Adjuvant Activity of ImmuneRegen's Viprovex(R) With Cancer Vaccine

Tue, 23 Sep 2008 05:30:00 EDT

SCOTTSDALE, AZ--(eMediaWorld - September 23, 2008) - ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announces a collaborative relationship with the University of North Carolina at Charlotte to evaluate ImmuneRegen's Viprovex as a possible cancer-vaccine adjuvant. Adjuvants are agents that stimulate and, subsequently, augment the immune system's response to a foreign antigen.

IBC Life Sciences Kicks off the Annual BioProcess International(TM) Conference & Exhibition in Anaheim, California

Mon, 22 Sep 2008 12:00:00 EDT

September 22-26, 2008 at the Disneyland Hotel

ORLive Presents: Prenatal Heart Diagnosis Case Discussions of Options and Treatments

Mon, 22 Sep 2008 10:28:00 EDT

Live Webcast: From Internationally Renowned Morgan Stanley Children's Hospital of NewYork-Presbyterian: October 8, 2008 7:30 AM EDT

$15,975,000 Investment by Philip Morris International in Medicago

Mon, 22 Sep 2008 09:18:00 EDT

QUEBEC CITY, QUEBEC--(eMediaWorld - Sept. 22, 2008) - Medicago Inc. ("Medicago") (TSX VENTURE:MDG) today announced that it has signed on September 19, 2008 a non-binding letter of intent with Philip Morris International ("PMI") for a private placement of 45,000,000 units (the "Units") at a price of $0.355 per Unit for proceeds of $15,975,000. The proceeds of the private placement will be used to further fund the development of Medicago's pandemic and seasonal influenza vaccines. "We are very pleased to expand our relationship with PMI which was previously identified as the Fortune 100 company in our press releases of April 7, 2008, February 7, 2008 and December 19, 2007. The investment demonstrates their commitment and confidence in our proprietary plant-based technology platform," said Andy Sheldon, President & CEO of Medicago. "This transaction provides us with the necessary capital to continue the development of our vaccine candidates and will bring additional expertise to further

Investissement de 15 975 000 $ de Philip Morris International dans Medicago

Mon, 22 Sep 2008 09:18:00 EDT

QUEBEC, QUEBEC--(eMediaWorld - 22 sept. 2008) - Medicago Inc. ("Medicago") (TSX:CROISSANCE:MDG) a annoncé aujourd'hui la signature le 19 septembre 2008 d'une lettre d'intention non exécutoire avec Philip Morris International Inc. ("PMI") relativement à un placement privé de 45 millions d'unités (les "unités") au prix unitaire de 0,355 $, pour un produit de 15 975 000 $. Le produit du placement privé sera utilisé pour financer la suite des activités de mise au point des vaccins de Medicago contre une pandémie de grippe et contre la grippe saisonnière.

Scientists at IBM and Genome Institute of Singapore Make New Stem Cell Discovery

Fri, 19 Sep 2008 12:50:00 EDT

Findings Show RNA Interference Has Much Larger Role in Cellular Functions and Processes Than Previously Thought

BioAlliance Pharma SA : a growing SME receives a prestigious award from the French State

Fri, 19 Sep 2008 11:16:00 EDT

PARIS--(eMediaWorld - September 19, 2008) - BioAlliance Pharma, a growing SME receives a prestigious award from the French State BioAlliance Pharma SA (Euronext Paris, ISIN code: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced that Madame Dominique Costantini, President of the company's Executive Board, had been awarded the Knight of the Legion of Honor insignia by Professor Claude Griscelli, a former Director of France's INSERM national institute of health and a member of the country's State Council.

Symbollon to Exhibit at the Natural Products Expo East

Thu, 18 Sep 2008 10:38:00 EDT

FRAMINGHAM, MA--(eMediaWorld - September 18, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is pleased to announce that it will be exhibiting at the Natural Products Expo East 2008 being held October 16th through 18th at the Boston Convention & Exhibition Center in Boston. Symbollon will be launching its dietary supplement, IoGenT at Expo East. IoGen is formulated to promote breast health for women. Over 40% of the nation's $51.4 billion natural products sales are generated on the eastern seaboard. Expo East is expecting over 20,000 attendees comprised of retailer buyers, distributors, brokers, manufacturers, suppliers, press and industry members.

Pfizer invite les Canadiens à être courageux et à tendre la main

Thu, 18 Sep 2008 08:00:00 EDT

La Fondation pour l'enfance Starlight Canada et Pfizer Canada s'associent pour lancer un site de ressources en ligne et un court-métrage au sujet du courage

Pfizer Encourages Canada to Reach Out and Be Brave

Thu, 18 Sep 2008 08:00:00 EDT

Starlight Children's Foundation Canada and Pfizer Canada Team Up to Debut Online Resource and a Short Film About Courage

GENEART Supports Advancements in Synthetic Biology as Partner of the iGEM Competition

Wed, 17 Sep 2008 05:00:00 EDT

REGENSBURG, GERMANY--(eMediaWorld - September 17, 2008) - - The iGEM ("International Genetically Engineered Machine") competition is the only competition of its kind. Its objective is the development of standardized DNA components for applications in Synthetic Biology - GENEART is sponsoring partner of this competition, supporting the organizers and the student teams and donating one of the main prizes - 84 Teams of students from all corners of the globe participate Regensburg, September 17, 2008 - Imagine organisms with an on/off switch, detecting poisons or flashing green! When young scientists in the field of Synthetic Biology compete for the first prize in the iGEM ("International Genetically Engineered Machine") competition, visions arise of commercial applications.

BioAlliance Pharma SA : announces participation in the MidCap Event on September 29 and 30, 2008

Tue, 16 Sep 2008 11:00:00 EDT

PARIS--(eMediaWorld - September 16, 2008) - BioAlliance Pharma SA (Euronext Paris: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it will participate in the MidCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 29 and Tuesday 30 of September in Paris. The MidCap Event will take place at the Palais Brongniart, 19 rue Notre-Dame des Victoires 75002 PARIS.

Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) Awards Cleveland BioLabs Contract to Develop Protectan CBLB502

Tue, 16 Sep 2008 10:30:00 EDT

BUFFALO, NY--(eMediaWorld - September 16, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) has awarded the Company a contract under the Broad Agency Announcement titled, "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation," for selected tasks in the advanced development of Protectan CBLB502. The total contract value including all milestone-based options is $13.3 million over a three-year period, with the first year's award of $3.4 million, commencing September 16, 2008.

ORLive Presents: Laparoscopic Gastric Sleeve Gastrectomy

Tue, 16 Sep 2008 09:44:00 EDT

Live Webcast: From Vanderbilt University Medical Center: October 23, 2008 6:00 PM CDT

Leading X-Ray Inspection Firm Expands Service Offerings

Tue, 16 Sep 2008 09:00:00 EDT

NEW HAVEN, CT--(eMediaWorld - September 16, 2008) - Total Quality Corporation (TQC), the nation's leading provider of temporary inspection systems, is pleased to announce a number of changes designed to meet the increasing demand for solutions that enable manufacturers to re-claim suspect product and provide a high level of quality control. "Having worked with hundreds of the leading food and personal care companies over the years to resolve their contaminant problems, it is exciting to be able to offer additional capabilities, including enhanced digital imaging systems, metal detection, and automated inspection systems," states Kymberly Seneco, Operations Manager for Total Quality.

Focus on the World Alzheimer's and Parkinson's Disease Market

Mon, 15 Sep 2008 06:51:00 EDT

LONDON, UNITED KINGDOM--(eMediaWorld - Sept. 15, 2008) - Reportlinker.com announces that a new market research report related to the Neurology industry is available in its catalogue. World Alzheimer's and Parkinson's Disease Market http://www.reportlinker.com/p092488/World-Alzheimers-and-Parkinsons-Disease-Market.html

Information Regarding UCB as an Issuer by Virtue of Articles 15 and 18 of the Law of 2 May 2007 on the Disclosure of Major Holdings, as of 1 September 2008

Fri, 12 Sep 2008 11:16:00 EDT

BRUSSELS, BELGIUM--(eMediaWorld - September 12, 2008) - According to article 29 of the law of 2 May 2007 on the disclosure of major holdings, UCB releases the following information: 1. Information to be provided for on the basis of article 15, §1, al. 1 - Total of the share capital : EUR 550.095.156 - Total number of financial instruments that are treated as voting securities: 183.365.052 (single class of financial instruments) - Total number of voting rights : 183.365.052 (single class of voting rights) 2. Additional information to be provided for on the basis of article 15, §1, al. 2 - Total number of convertible obligations : 0 - Total number of rights (materialized or not in financial instruments) to subscribe to yet un-issued financial instruments treated as voting securities: -- 209.000 warrants, giving, in case they are all exercised, a total number of 209.000 voting rights -- 30.000.000 conditio

Publication in Accordance With the Act of 2 May 2007 Regarding the Publication of Major Shareholdings

Fri, 12 Sep 2008 11:08:00 EDT

GHENT, BELGIUM--(eMediaWorld - September 12, 2008) - Ablynx (Euronext Brussels: ABLX), a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, published today the information in accordance with Articles 15, 18 and 29 of the Belgian Act of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Act"). In accordance with the Act, Ablynx NV published the following information:

RxElite Responds to Minrad International Notice of Non-Exclusive Supplier Arrangements

Fri, 12 Sep 2008 10:58:00 EDT

MERIDIAN, ID--(eMediaWorld - September 12, 2008) - RxElite, Inc. (OTCBB: RXEI), which develops and markets generic prescription drug products in specialty generic markets in the areas of anesthesia, sterile liquid dose drugs (which includes ophthalmic and sterile inhalation respiratory products and injectable drugs), and active pharmaceutical ingredients (API), today announced that it had received a letter from its supplier, Minrad International, Inc. Minrad is RxElite's supplier of Isoflurane, Sevoflurane and Enflurane. The letter is seeking to exercise rights under an exclusive distribution agreement and claiming that RxElite was in default under its agreement. RxElite stated that it is in continuing discussions with Minrad and was surprised by the unilateral action by Minrad it received in the midst of ongoing global discussions concerning product and supply arrangements.